Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab

Journal of the American Academy of Dermatology

Volumn 59, Issue 6, 2008, Pages 953-957

  Morales, Anjali V ^a   Advani, Ranjana ^a   Horwitz, Steven M ^b   Riaz, Nadeem ^a   Reddy, Sunil ^a   Hoppe, Richard T ^a   Kim, Youn H ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; SKIN LYMPHOMA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 55949095123     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.08.005     Document Type: Article

References (32)

1. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swendlow SH., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768-3785
2. Willemze R. Primary cutaneous B-cell lymphoma: classification and treatment. Curr Opin Oncol 16 (2006) 425-431
3. Smith B.D., Glusac E.G., McNiff J.M., Smith G.L., Heald P.W., Copper D.L., et al. Primary cutaneous B-cell lymphomas treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 22 (2004) 634-639
4. Kirova Y.M., Piedbois Y., and Le Bourgeois J.P. Radiotherapy in the management of cutaneous B-cell lymphoma: our experience in 25 cases. Radiother Oncol 52 (1999) 15-18
5. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 59 (2008) 237-250
6. + cytotoxic T cells. Leukemia 15 (2001) 1619-1626
7. Bello C., and Sotomayor E.M. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond (ASCO meeting). Hematology (2007) 233-242
8. Coiffier B. Treatment of non-Hodgkin's lymphoma: a look over the past decade. Clin Lymphoma Myeloma 7 Suppl (2006) S7-S13
9. Marcus R., Imrie K., Belch A., Cunnigham D., Flores E., Catalano J., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005) 1417-1423
10. Habermann T.M., Weller E.A., Morrison V.A., Gascoyne R.D., Cassileth P.A., Cohn J.B., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24 (2006) 3121-3127
11. Maloney D.G. Rituximab for follicular lymphoma. Curr Hematol Rep 2 (2003) 13-22
12. Paul T., Radny P., Krober S.M., Paul A., Blaheta H.J., and Garbe C. Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 144 (2001) 1239-1243
13. Gellrich S., Muche J.M., Pelzer K., Audring H., and Sterry W. Anti-CD20 antibodies in primary cutaneous B-cell lymphoma: initial results in dermatologic patients. Hautarzt 52 (2001) 205-210
14. Soda R., Costanzo A., Cantonetti M., Orland A., Bianchi L., and Chimenti S. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol 81 (2001) 207-208
15. Massengale W.T., McBurney E., and Gurtler J. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. J Am Acad Dermatol 46 (2002) 441-443
16. Kennedy G.A., Blum R., McCormack C., and Prince H.M. Treatment of primary cutaneous follicular center lymphoma with rituximab: a report of two cases. Australas J Dermatol 45 (2004) 34-37
17. Lacouture M.E., Baron J.M., Jani A.B., Laumann A.E., and Soltani K. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody. Clin Exp Dermatol 30 (2005) 46-48
18. Roguedas A.M., Watier H., Paintaud G., de Muret A., Vaillant L., and Machel L. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma. Br J Dermatol 152 (2005) 541-544
19. Errante D., Bernardi D., Bianco A., De Nardi S., and Salvagno L. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma. Ann Oncol 17 (2006) 1720-1721
20. Schneider L.A. Cutaneous B-cell lymphoma treated with rituximab infusions. Acta Derm Venerol 86 (2006) 550-551
21. Kyrstonis M.C., Siakantaris M.P., Kalpadakis C., Dimopoulou M.N., Vassilakopoulos T.P., Kontopidou F.N., et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol 77 (2006) 300-303
22. Kerl K., Prins C., Saurat J.H., and French L.E. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 155 (2006) 1197-1200
23. Fink-Puches R., Wolf I.G., Zalaudek I., Kerl H., and Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 52 (2005) 847-853
24. Gitelson E., Al-Saleem T., Millenson M., Lessin S., and Smith M.R. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature. Leuk Lymphoma 47 (2006) 1902-1907
25. Gellrich S., Muche J.M., Wilks A., Jasch K.C., Voit C., Fischer T., et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-an applicational observation. Br J Dermatol 153 (2005) 167-173
26. Lossos I.S., Morgensztern D., Blaya M., Alencar A., Pereira D., and Rosenblatt J. Rituximab for treatment of chemoimmunotherapy naïve marginal zone lymphoma. Leuk Lymphoma 48 (2007) 1630-1632
27. Jazirehi A.R., Vega M.I., and Bonavid B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 67 (2007) 1270-1281
28. Hernandez-Illizaliturri F.J. Impaired calcium mobilization in rituximab-resistant cells is associated with changes in the structure of CD20 antigen. J Clin Oncol 24 (2006) 2516
29. Wobser M., Voigt H., Eggert A.O., Houben R., Kauczok C.S., Brocker E.B., et al. Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. B J Cancer 96 (2007) 1540-1543
30. Cartron G., Dacheux K., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Gc receptor FcgammaR111a gene. Blood 99 (2002) 754-758
31. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947
32. Heinzerling L.M., Urbanek M., Funk J.O., Peker S., Bleck O., Neuber K., et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 89 (2000) 1835-1844